Nine benefits of using terbinafine Review article
Article Sidebar
Published:
Jun 30, 2014
Keywords:
terbinafine, treatment, mycosis, toenails mycosis
Main Article Content
Abstract
Terbinafine is an allilamine, which has an effect of the fungicidal activity. It is used for treatment of dermatophytes, non-dermatophytes and mixed fungal infections. The reurrence in the long-term follow-up observation was seldom noted. This drug is well tolerated by patients and it rarely interacts with other medicines. Moreover, several studies have demonstrated the high effectiveness of terbinafine.
Article Details
How to Cite
Nowicki , R., & Malinowska, A. (2014). Nine benefits of using terbinafine. Medycyna Faktow (J EBM), 7(2(23), 44-47. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2366
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Lesiak A., Rogowski-Tylman M., Narbutt J. et al.: Grzybica paznokci – itrakonazol czy terbinafina? Dermatologia Kliniczna 2011; 13(3): 161-166.
2. Szepietowski J.: Grzybice skóry i paznokci. Vademecum lekarza praktyka. Wydawnictwo Medycyna Praktyczna, Kraków 2001: 138-146.
3. Adamski Z., Batura-Gabryel H.: Mikologia lekarska dla lekarzy i studentów. Wydawnictwo Naukowe Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, 2007: 98-110.
4. Szepietowski J., Reich A.: Skojarzone leczenie terbinafiną i amorfiną grzybicy paznokci stóp – otwarte badanie prospektywne. Dermatologia Kliniczna 2008; 10(2): 67-71.
5. Barber K., Barber J.: Onychomycosis: Therapy directed by morphology and mycology. Skin Therapy Lett., 2009; 14, 1-2.
6. Gupta A.K., Cooper E.A.: A simple algorithm for the treatment of dermatophyte toenail onychomycosis. Skin Therapy Lett. Family Practice 2008; 4: 1-3.
7. Reich A., Szepietowski J., Baran E.: Nurtujące aspekty leczenia terbinafiną. Mikol. Lek. 2004; 11(1): 77-80.
8. Balfour J.A., Faulds D.: Terbinafine: a review of its pharmocodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43, 259-284.
9. Shear N.H., Villars V.V., Marsolais Ch.: Terbinafine: an oral and topical antifungal agent. Clinics Dermatol. 1992; 9: 487-495.
10. Ryder N.S.: The mechanism of action of terbinafine. Clin. Exp. Dermatol. 1989; 14: 98-100.
11. Elewski B.E.: Onychomycosis: pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 1998; 11: 415-429.
12. Ghannoum M.A., Elewski B.: Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin. Diag. Lab. Immunol. 1999; 6: 921-923.
13. Reich A., Szepietowski J., Baran E.: Terbinafina w leczeniu zakażeń niedermatofitowych i mieszanych zakażeń grzybiczych paznokci. Mikol. Lek. 2003; 10: 145-148.
14. Gupta A.K., Gregurek-Novak T.: Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-238.
15. de Doncker P.: Pharmacokinetics of oral antifungal agents. Dermatol. Ther. 1997; 3: 46-57.
16. Goodfield M.J.D.: Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br. J. Dermatol. 1992; 126: 33-35.
17. Van der Schroeff J.G., Cirkel P.K.S., Crijns M.B. et al.: A randomized treatment duration-finding study of terbinafine in onychomycosis. Br. J. Dermatol. 1992; 126: 36-39.
18. Svejgaard E.L., Brandrup F., Kragballe K. et al.: Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months’ follow-up. Acta Dermatol. Venereol. 1997; 77: 66-69.
19. De Cuyper C., Hindryckx P.H.: Long-term outcomes in the treatment of toenail onychomycosis. Br. J. Dermatol. 1999, 141, Suppl. 56: 15-20.
20. Sigurgeirsson B., Olaffson J.H., Steinsson J. et al.: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. A 5-years blinded prospective follow-up study. Arch. Dermatol. 2002; 138: 353-357.
21. Gliński W., Baran E., Nowicki R. et al.: Konsensus dotyczący leczenia powierzchownych zakażeń grzybiczych. Przegl. Dermatol. 2002; 89: 85-92.
22. Gupta A.K., Konnikov N., Lunde C.W.: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J. Am. Acad. Dermatol. 2001; 44: 479-484.
23. Smith E.B., Stein L.F., Fivenson D.P. et al.: Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. Int. J. Dermatol. 2003; 2: 31-34.
24. Gupta A.K., Skinder A.R., Baran R.: Onychomycosis in children: an overview. J. Drugs Dermatol. 2003; 2: 31-34.
25. Aly R., Berger T.: Common superficial fungal infections in patients with AIDS. Clin. Infect. Dis. 1996; 22: S128-S132.
26. Rongioletti F., Persi A., Tripodi S. et al.: Proximal white subungual onychomycosis: a sign of immunodeficiency. J. Am. Acad. Dermatol. 1994; 30: 129-130.
27. Elmets C.A.: Management of common superficial fungal infections in patients with AIDS. J. Am. Acad. Dermatol. 1994; 31: S60-S63.
28. Herranz P., Garcia J., Lucas R. et al.: Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br. J. Dermatol. 1997; 137: 577-580.
29. Adamski Z., Hasse-Cieślińska M., Deja M.: Nowoczesne leki stosowane w terapii dermatomikoz. Przew. Lek. 2004; 6: 70-77.
2. Szepietowski J.: Grzybice skóry i paznokci. Vademecum lekarza praktyka. Wydawnictwo Medycyna Praktyczna, Kraków 2001: 138-146.
3. Adamski Z., Batura-Gabryel H.: Mikologia lekarska dla lekarzy i studentów. Wydawnictwo Naukowe Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, 2007: 98-110.
4. Szepietowski J., Reich A.: Skojarzone leczenie terbinafiną i amorfiną grzybicy paznokci stóp – otwarte badanie prospektywne. Dermatologia Kliniczna 2008; 10(2): 67-71.
5. Barber K., Barber J.: Onychomycosis: Therapy directed by morphology and mycology. Skin Therapy Lett., 2009; 14, 1-2.
6. Gupta A.K., Cooper E.A.: A simple algorithm for the treatment of dermatophyte toenail onychomycosis. Skin Therapy Lett. Family Practice 2008; 4: 1-3.
7. Reich A., Szepietowski J., Baran E.: Nurtujące aspekty leczenia terbinafiną. Mikol. Lek. 2004; 11(1): 77-80.
8. Balfour J.A., Faulds D.: Terbinafine: a review of its pharmocodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses. Drugs 1992; 43, 259-284.
9. Shear N.H., Villars V.V., Marsolais Ch.: Terbinafine: an oral and topical antifungal agent. Clinics Dermatol. 1992; 9: 487-495.
10. Ryder N.S.: The mechanism of action of terbinafine. Clin. Exp. Dermatol. 1989; 14: 98-100.
11. Elewski B.E.: Onychomycosis: pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 1998; 11: 415-429.
12. Ghannoum M.A., Elewski B.: Successful treatment of fluconazole-resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin. Diag. Lab. Immunol. 1999; 6: 921-923.
13. Reich A., Szepietowski J., Baran E.: Terbinafina w leczeniu zakażeń niedermatofitowych i mieszanych zakażeń grzybiczych paznokci. Mikol. Lek. 2003; 10: 145-148.
14. Gupta A.K., Gregurek-Novak T.: Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-238.
15. de Doncker P.: Pharmacokinetics of oral antifungal agents. Dermatol. Ther. 1997; 3: 46-57.
16. Goodfield M.J.D.: Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial. Br. J. Dermatol. 1992; 126: 33-35.
17. Van der Schroeff J.G., Cirkel P.K.S., Crijns M.B. et al.: A randomized treatment duration-finding study of terbinafine in onychomycosis. Br. J. Dermatol. 1992; 126: 36-39.
18. Svejgaard E.L., Brandrup F., Kragballe K. et al.: Oral terbinafine in toenail dermatophytosis. A double-blind, placebo-controlled multicenter study with 12 months’ follow-up. Acta Dermatol. Venereol. 1997; 77: 66-69.
19. De Cuyper C., Hindryckx P.H.: Long-term outcomes in the treatment of toenail onychomycosis. Br. J. Dermatol. 1999, 141, Suppl. 56: 15-20.
20. Sigurgeirsson B., Olaffson J.H., Steinsson J. et al.: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. A 5-years blinded prospective follow-up study. Arch. Dermatol. 2002; 138: 353-357.
21. Gliński W., Baran E., Nowicki R. et al.: Konsensus dotyczący leczenia powierzchownych zakażeń grzybiczych. Przegl. Dermatol. 2002; 89: 85-92.
22. Gupta A.K., Konnikov N., Lunde C.W.: Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly. J. Am. Acad. Dermatol. 2001; 44: 479-484.
23. Smith E.B., Stein L.F., Fivenson D.P. et al.: Clinical trial: the safety of terbinafine in patients over the age of 60 years: a multicenter trial in onychomycosis of the feet. Int. J. Dermatol. 2003; 2: 31-34.
24. Gupta A.K., Skinder A.R., Baran R.: Onychomycosis in children: an overview. J. Drugs Dermatol. 2003; 2: 31-34.
25. Aly R., Berger T.: Common superficial fungal infections in patients with AIDS. Clin. Infect. Dis. 1996; 22: S128-S132.
26. Rongioletti F., Persi A., Tripodi S. et al.: Proximal white subungual onychomycosis: a sign of immunodeficiency. J. Am. Acad. Dermatol. 1994; 30: 129-130.
27. Elmets C.A.: Management of common superficial fungal infections in patients with AIDS. J. Am. Acad. Dermatol. 1994; 31: S60-S63.
28. Herranz P., Garcia J., Lucas R. et al.: Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br. J. Dermatol. 1997; 137: 577-580.
29. Adamski Z., Hasse-Cieślińska M., Deja M.: Nowoczesne leki stosowane w terapii dermatomikoz. Przew. Lek. 2004; 6: 70-77.